Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sarver

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Molecular Medicine (Cambridge, Mass.)|July 1, 1995
HIV accessory proteins: emerging therapeutic targetsR H Miller, N Sarver
Clinical Microbiology Reviews|July 1, 1995
Nucleic acid vaccinesF R Vogel, N Sarver
Advances in Experimental Medicine and Biology|January 1, 1992
Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agentsJ J Rossi, N Sarver
Antisense Research and Development|January 1, 1991
Meeting Report. Ribozymes: progress and prospects of catalytic RNA as therapeutic agentsL Chrisey, J Rossi, N Sarver
Advances in Pharmacology (San Diego, Calif.)|January 1, 1994
Antisense catalytic RNAs as therapeutic agentsD Castanotto, J J Rossi, N Sarver
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1982
Transformation and replication in mouse cells of a bovine papillomavirus--pML2 plasmid vector that can be rescued in bacteriaN Sarver, J C Byrne, P M Howley
Research in Virology|January 1, 1992
Molecular characterization of HIV1 Nef proteinJ Kaminchik, N Sarver, M Gorecki, et al.
Trends in Pharmacological Sciences|August 1, 1989
HIV proteinase as a target for drug actionM I Johnston, H S Allaudeen, N Sarver
Methods in Enzymology|January 1, 1983
Eukaryotic cloning vectors derived from bovine papillomavirus DNAP M Howley, N Sarver, M F Law
Nucleic Acids Research|September 11, 1987
Optimizing gene expression in BPV-transformed cells: effects of cell type on enhancer/promoter interactionD R Hurwitz, R Hodges, W Drohan, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Molecular Medicine (Cambridge, Mass.)|July 1, 1995
HIV accessory proteins: emerging therapeutic targetsR H Miller, N Sarver
Clinical Microbiology Reviews|July 1, 1995
Nucleic acid vaccinesF R Vogel, N Sarver
Advances in Experimental Medicine and Biology|January 1, 1992
Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agentsJ J Rossi, N Sarver
Antisense Research and Development|January 1, 1991
Meeting Report. Ribozymes: progress and prospects of catalytic RNA as therapeutic agentsL Chrisey, J Rossi, N Sarver
Advances in Pharmacology (San Diego, Calif.)|January 1, 1994
Antisense catalytic RNAs as therapeutic agentsD Castanotto, J J Rossi, N Sarver
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1982
Transformation and replication in mouse cells of a bovine papillomavirus--pML2 plasmid vector that can be rescued in bacteriaN Sarver, J C Byrne, P M Howley
Research in Virology|January 1, 1992
Molecular characterization of HIV1 Nef proteinJ Kaminchik, N Sarver, M Gorecki, et al.
Trends in Pharmacological Sciences|August 1, 1989
HIV proteinase as a target for drug actionM I Johnston, H S Allaudeen, N Sarver
Methods in Enzymology|January 1, 1983
Eukaryotic cloning vectors derived from bovine papillomavirus DNAP M Howley, N Sarver, M F Law
Nucleic Acids Research|September 11, 1987
Optimizing gene expression in BPV-transformed cells: effects of cell type on enhancer/promoter interactionD R Hurwitz, R Hodges, W Drohan, et al.
Pageof 4